Attached files
| file | filename |
|---|---|
| S-1 - S-1 - Gain Therapeutics, Inc. | nt10015006x7_s1.htm |
| EX-10.7 - EXHIBIT 10.7 - Gain Therapeutics, Inc. | nt10015006x7_ex10-7.htm |
| EX-21.1 - EXHIBIT 21.1 - Gain Therapeutics, Inc. | nt10015006x7_ex21-1.htm |
| EX-10.6 - EXHIBIT 10.6 - Gain Therapeutics, Inc. | nt10015006x7_ex10-6.htm |
| EX-4.2 - EXHIBIT 4.2 - Gain Therapeutics, Inc. | nt10015006x7_ex4-2.htm |
| EX-10.11 - EXHIBIT 10.11 - Gain Therapeutics, Inc. | nt10015006x7_ex10-11.htm |
| EX-10.10 - EXHIBIT 10.10 - Gain Therapeutics, Inc. | nt10015006x7_ex10-10.htm |
| EX-10.5 - EXHIBIT 10.5 - Gain Therapeutics, Inc. | nt10015006x7_ex10-5.htm |
| EX-10.3 - EXHIBIT 10.3 - Gain Therapeutics, Inc. | nt10015006x7_ex10-3.htm |
| EX-10.8 - EXHIBIT 10.8 - Gain Therapeutics, Inc. | nt10015006x7_ex10-8.htm |
| EX-10.4 - EXHIBIT 10.4 - Gain Therapeutics, Inc. | nt10015006x7_ex10-4.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated February 19, 2021, in the Registration Statement (Form
S-1) and related Prospectus of Gain Therapeutics, Inc. for the registration of its common stock.
/s/ Ernst & Young AG
Lancy- Geneva, Switzerland
February 19, 2021